J Respir Med Lung Dis | Volume 3, Issue 1 | Case Report | Open Access

Abdominal Aneurysm Rupture with Aorto-Caval Fistula after Bevacizumab Therapy: A Case Report

Thibaut Capron¹, Fabien Beranger¹, Philippe Goutorbe¹, Marie Lapierre¹, Hélène Barazzutti¹, Henri Berard¹ and Nicolas Paleiron^1*

¹Department of Pneumology, Hospital Instruction of Armées Sainte-Anne, France
²Department of Vascularsurgery, Hospital Instruction of Armées Sainte-Anne, France
³Department of Intensive Care, Hospital Instruction of Armées Sainte-Anne, France
⁴Department of Radiology, Hospital Instruction of Armées Sainte-Anne, France

^*Correspondance to: Nicolas Paleiron 

Fulltext PDF

Abstract

Bevacizumab is a monoclonal antibody, commonly used for treatment of stage IV non small cell lung cancer. We report the case of a patient which presented with a bevacizumab-induced aorto-caval fistula. The causality is based on the fact that no pre existing vascular abnormality was described on previous CT-scan. A surgical treatment was realized and is described in this report.

Keywords:

Abdominal aneurysm rupture; Bevacizumab; Anti-angiogenic; Aorto-caval fistula

Citation:

Capron T, Beranger F, Goutorbe P, Lapierre M, Barazzutti H, Berard H, et al. Abdominal Aneurysm Rupture with Aorto-Caval Fistula after Bevacizumab Therapy: A Case Report. J Respir Med Lung Dis. 2018; 3(1): 1031.